Lung Cancer Quality Performance Indicator Specifications

LCQI07 Systemic Anti‑cancer Therapy

2021

Citation: Te Aho o Te Kahu. 2021. *Lung Cancer Quality Performance Indicator Specifications: LCQI07 Systemic Anti-cancer Therapy*. Wellington: Te Aho o Te Kahu.

Published in March 2021 by the Te Aho o Te Kahu
PO Box 5013, Wellington 6140, New Zealand

ISBN 978-1-99-002988-2 (online)
HP 7603



This document is available at teaho.govt.nz

|  |  |
| --- | --- |
| **CCBY** | This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to: share ie, copy and redistribute the material in any medium or format; adapt ie, remix, transform and build upon the material. You must give appropriate credit, provide a link to the licence and indicate if changes were made. |

Contents

[Introduction 1](#_Toc65490852)

[Sources of data for indicator 1](#_Toc65490853)

[LCQI07 Systemic anti-cancer therapy 2](#_Toc65490854)

[Measure items 2](#_Toc65490855)

[Case eligibility criteria (denominator) 3](#_Toc65490856)

[Numerator criteria 5](#_Toc65490857)

[Chemotherapy drug codes and names 6](#_Toc65490858)

# Introduction

This information is provided to make it easier for analysts to replicate our calculations. For each measure we have provided supporting information, a table and a flow diagram.

This document provides specifications for the following measure.

|  |  |  |
| --- | --- | --- |
| **Measure** | **Measure abbreviation** | **Measure type** |
| a) Proportion of people with non-small cell lung cancer receiving systemic anti-cancer therapy | NSCLC\_SACT | Quality improvement |
| b) Proportion of people with small cell lung cancer receiving systemic anti-cancer therapy | SCLC\_SACT | Quality improvement |

# Sources of data for indicator

* New Zealand Cancer Registry (NZCR) – a population-based register of all primary malignant diseases diagnosed in New Zealand, excluding squamous and basal cell skin cancers
* Pharmaceutical Collection (PHARMS) – a data warehouse that supports the management of pharmaceutical subsidies, and contains claim and payment information from pharmacists for subsidised dispensings

More information on these data sources can be found on the Ministry of Health’s website: [www.health.govt.nz](http://www.health.govt.nz).

# LCQI07Systemic anti-cancer therapy

a) Proportion of people with non-small cell lung cancer receiving systemic anti-cancer therapy.

b) Proportion of people with small cell lung cancer receiving systemic anti-cancer therapy.

**Measure type:** quality improvement

## Measure items

| **Dataset** | **Data item** | **Description** |
| --- | --- | --- |
| NZCR | NHI | Patient identifier |
| NZCR | Cancer event ID | Cancer registration identifier |
| NZCR | Date of initial diagnosis | Date person first diagnosed with lung cancer |
| NZCR | Diagnosis year | Calendar year of first diagnosis |
| NZCR | Site | Primary organ of origin of the cancer (ICD-10-AM 8th Edition code) |
| NZCR | Morphology code | 4-digit code (ICD-O-3) for microscopic or cellular anatomy of the cancer  |
| NZCR | Basis | Basis of diagnosis |
| NZCR | DHB of domicile | DHB code for domicile of patient at diagnosis |
| NZCR | DHB | DHB name based on domicile of patient at diagnosis |
| NZCR | Age at diagnosis | Age of patient at diagnosis in years |
| NZCR | Prioritised ethnicity | Ethnic group derived from patient’s ethnicity |
| NZCR | Sex | Sex of patient |
| NZCR | Deprivation quintile | NZDep2013 index of social deprivation quintile based on patient’s domicile |
| NZCR | Date of death | Date patient died |
| NZCR | TNM\_T | Stage at diagnosis – tumour |
| NZCR | TNM\_N | Stage at diagnosis – node |
| NZCR | TNM\_M | Stage at diagnosis – metastases |
| NZCR | Behaviour code | Neoplastic behaviour of the cancer |
| NZCR | Multiple tumour flags | Person diagnosed with more than one tumour |
| NZCR | Registration status code | Status of registration processing |
| PHARMS | Date of dispensing | Date of dispensing of chemotherapy drugs |
| PHARMS | Funding DHB code | Code of DHB of service |
| PHARMS | Funding DHB | DHB of service for patient |
| PHARMS | Chemical ID | Identifier for drug |
| PHARMS | Chemical name | Name of chemotherapy drug |

## Case eligibility criteria (denominator)

### a) NSCLC

|  |  |  |  |
| --- | --- | --- | --- |
| **Diagram reference** | **Assessment** | **Item** | **Codes** |
| 1 | First or only diagnosis of malignant neoplasm | Primary site | First diagnosis of lung cancer (trachea C33 or bronchus C34) |
| 2 | Exclude manually censored case | Exclusion | Registration codes not R\_C (registered complete) or R\_R (registered)No incident cancer (exclude people with multiple tumour flags = yes)People diagnosed following death certificate only (basis = 0)People domiciled outside of New Zealand (DHB\_code = 999)Cancer morphologies of melanoma, sarcoma and other unusual morphologies (codes 8333, 8720, 8772, 8800, 8801, 8803, 8805, 8815, 8890, 9040, 9041, 9133) |
| 3 | Diagnosis date | Date of initial diagnosis | 2015–18 |
| 4 | Male or female | Sex | M or F |
| 5 | Adult patient 18 years and older at diagnosis | Age at diagnosis | 18 years and older |
| 6 | Invasive tumours | Behaviour code | 3 |
| 7 | Non-small cell lung cancer | Morphology code | Include all morphology codes except codes for SCLC (8041, 8042, 8043, 8044 and 8054) and other/unspecified lung cancers (8000, 8010, 8020, 8240, 8244, 8249) |

### b) SCLC

|  |  |  |  |
| --- | --- | --- | --- |
| **Diagram reference** | **Assessment** | **Item** | **Codes** |
| 1 | First or only diagnosis of malignant neoplasm | Primary site | First diagnosis of lung cancer (trachea C33 or bronchus C34) |
| 2 | Exclude manually censored case | Exclusion | Registration codes not R\_C (registered complete) or R\_R (registered)No incident cancer (exclude people with multiple tumour flags = yes)People diagnosed following death certificate only (basis = 0)People domiciled outside of New Zealand (DHB\_code = 999)Cancer morphologies of melanoma, sarcoma and other unusual morphologies (codes 8333, 8720, 8772, 8800, 8801, 8803, 8805, 8815, 8890, 9040, 9041, 9133) |
| 3 | Diagnosis date | Date of initial diagnosis | 2015–18 |
| 4 | Male or female | Sex | M or F |
| 5 | Adult patient 18 years and older at diagnosis | Age at diagnosis | 18 years and older |
| 6 | Invasive tumours | Behaviour code | 3 |
| 7 | Small cell lung cancer | Morphology code | Include SCLC morphology codes (80413, 80423, 80433, 80443 and 80543) |

## Numerator criteria

### a) NSCLC

|  |  |  |  |
| --- | --- | --- | --- |
| **Diagram reference** | **Assessment** | **Item** | **Codes** |
| 8 | Number of people with non-small cell lung cancer who receive systemic anti‑cancer therapy | NSCLC\_SACT | Drugs with chemical ID 3826, 3825, 2433, 3847, 3811, 3815, 3834, 3842, 3816, 4088, 3966, 3916, 1369, 3813, 2319, 2320 |

### b) SCLC

|  |  |  |  |
| --- | --- | --- | --- |
| **Diagram reference** | **Assessment** | **Item** | **Codes** |
| 8 | Number of people with small cell lung cancer who receive platinum-etoposide based systemic anti‑cancer therapy | SCLC\_SACT  | Drugs with chemical ID 3826, 3825, 2433, 3847, 3811, 3815, 3834, 3842, 3816, 4088, 3966, 3916, 1369, 3813, 2319, 2320anddispensed date between -30 and 275 days from diagnosis date |

## Chemotherapy drug codes and names

|  |  |
| --- | --- |
| **Chemical ID** | **Chemical name**  |
| 3826 | Cisplatin |
| 3825 | Carboplatin |
| 2433 | Etoposide |
| 3847 | Etoposide phosphate |
| 3811 | Irinotecan hydrochloride |
| 3815 | Paclitaxel |
| 3834 | Docetaxel |
| 3842 | Gemcitabine hydrochloride |
| 3816 | Vinorelbine |
| 4088 | Pemetrexed |
| 3966 | Gefitinib |
| 3916 | Erlotinib hydrochloride |
| 1369 | Cyclophosphamide |
| 3813 | Doxorubicin |
| 2319 | Vinblastine sulphate |
| 2320 | Vincristine sulphate |

### a) NSCLC



### b) SCLC

